Dihexa and brain repair: what the science actually supports

What did @drkendalstewart actually say?

Stewart's core argument is that two growth factors, BDNF and NGF, act as cellular foremen: they don't build anything directly, but they tell neurons to absorb fats, proteins, and cholesterol needed for repair. He then argues that some people have "mutated" versions of these factors, which explains why certain concussion patients recover in a week while others stay symptomatic for a year. His proposed solution is dihexa, which he says hits a receptor called c-MET and tells cells to "take up nutrition and start to repair itself." He credits the peptide's discovery to Washington State University and describes it as a fragment of a stress hormone. The video's caption adds that dihexa "targets neurotrophic factors like BDNF and NGF, which drive brain repair."

That's a lot of mechanistic ground to cover in a short clip, and not all of it lands cleanly on the evidence.

Does the science back this up?

Partially, and the devil is in how far you push the claims. The basic neurobiology of BDNF and NGF is real. Both are well-established neurotrophins that support neuronal survival, synaptic plasticity, and recovery after injury. The c-MET receptor connection to dihexa is also real, at least in animal models.

Dihexa (also written N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Joseph Bhatt and colleagues. It was designed as a hepatocyte growth factor (HGF) mimetic. HGF binds to c-MET, and c-MET signaling does support neuronal repair and synaptogenesis. Bhatt et al. (2013, Journal of Pharmacology and Experimental Therapeutics) showed dihexa improved performance in a rat model of cognitive impairment. The effect sizes were notable in rodents. However, there is currently zero published human clinical trial data on dihexa. None. That gap between "works in rats" and "works in people with concussions" is enormous, and Stewart does not mention it once.

His framing of BDNF and NGF as things that tell cells to "take up nutrition" is a loose but not entirely wrong simplification of downstream anabolic signaling. These pathways do influence metabolic activity in neurons via PI3K/Akt and MAPK signaling cascades (Huang and Reichardt, 2001, Annual Review of Neuroscience).

What did they get wrong (or right)?

Let's split this honestly. Stewart gets credit for correctly identifying dihexa's WSU origin, its HGF-mimetic mechanism, and the general concept that neurotrophic signaling differences could explain variable concussion recovery. That's not nothing.

But the claim that he can look at a slow-recovering concussion patient and say "you're probably mutated" is a problem. Genetic variants in BDNF (particularly the Val66Met polymorphism) do affect concussion recovery trajectories, and there is real research here (Lipsky and Bhatt, 2013, Neuroscience and Biobehavioral Reviews). But Stewart presents this like a routine clinical insight his practice acts on confidently. No diagnostic framework is described, no validation study is cited, and he phrases it as "we look like gurus." That framing should make you uncomfortable. It's confident speculation dressed up as clinical pattern recognition.

Calling BDNF and NGF "repair nuclear factors" is also inaccurate. They are not nuclear factors. They are secreted proteins that bind membrane receptors. Their downstream signaling can affect gene transcription, but that is not what the phrase "nuclear factors" means in biology. It's a small error but suggests the explanation was improvised.

What should you actually know?

Here is what you can actually take away from the underlying science, stripped of the marketing gloss. Dihexa is a research peptide with no FDA approval for any indication. It has shown cognitive benefits in rodent models via c-MET agonism, and that mechanism is biologically plausible. Whether that translates to humans recovering from traumatic brain injury is genuinely unknown. No phase I or phase II trial has been published.

The BDNF Val66Met polymorphism is a legitimate area of research in concussion recovery. It affects activity-dependent BDNF secretion. People with the Met allele show different recovery curves in some studies (McAllister et al., 2012, Journal of Neurotrauma). But knowing someone carries a variant and knowing that dihexa will help them are two completely separate questions, and the second one has no clinical evidence base yet.

If you are considering any peptide for cognitive recovery, you should know that compounded peptides are not equivalent to anything that has cleared clinical trials. The "it works through a real mechanism" argument is necessary but not sufficient for safety or efficacy. Mechanism plus rodent data is a hypothesis, not a treatment protocol.